A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

NCT03234400 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

COMBINATION_PRODUCT: Dapivirine Vaginal Ring, 25 mg
COMBINATION_PRODUCT: Dapivirine Vaginal Ring, 100 mg
COMBINATION_PRODUCT: Dapivirine Vaginal Ring, 200 mg

Sponsor

International Partnership for Microbicides, Inc.

Collaborators

[object Object]
[object Object]